Wieland Capital

Cycuria Therapeutics is a biotechnology company focused on developing innovative protein-based therapies for treating blood cancers, with a particular emphasis on acute myeloid leukemia (AML). The company's approach involves creating engineered proteins that selectively target and eliminate leukemic stem cells and AML blasts, while preserving healthy blood cells. This targeted strategy aims to reduce treatment-related toxicity, stimulate the immune system, and improve overall patient outcomes for AML and potentially other challenging cancer types.

Noscendo GmbH is a diagnostics company based in Duisburg, Germany, specializing in bioinformatics solutions for the identification and assessment of pathogens associated with bloodstream infections. The company utilizes Next Generation Sequencing (NGS) to enable intensive care clinicians to detect bacteria, fungi, viruses, and parasites from a single standard blood draw, without the need for prior cultivation or detailed knowledge of the infection's nature. Its proprietary algorithms assess the relevance of each identified pathogen, allowing for precise differentiation between commensals, contamination, and actual infection. Noscendo's innovative platform aims to enhance the efficiency and accuracy of pathogen detection in clinical settings.

Lifespin is a data-driven company that specializes in mapping human health conditions through a scalable platform. It utilizes advanced technology to digitize and analyze metabolomes on a population level, enabling the generation of metabolic insights for precision medicine. By transforming blood samples into digital formats, Lifespin creates a digital twin of each patient, using AI-enhanced Nuclear Magnetic Resonance (NMR) techniques to measure metabolic profiles. The company has established baseline metrics for human health, allowing for the identification of individual deviations. Lifespin's digital products are designed for healthcare providers and patients, facilitating early disease detection and ongoing health monitoring while offering moderate-cost health testing for preventative care and diagnostics.

Noscendo GmbH is a diagnostics company based in Duisburg, Germany, specializing in bioinformatics solutions for the identification and assessment of pathogens associated with bloodstream infections. The company utilizes Next Generation Sequencing (NGS) to enable intensive care clinicians to detect bacteria, fungi, viruses, and parasites from a single standard blood draw, without the need for prior cultivation or detailed knowledge of the infection's nature. Its proprietary algorithms assess the relevance of each identified pathogen, allowing for precise differentiation between commensals, contamination, and actual infection. Noscendo's innovative platform aims to enhance the efficiency and accuracy of pathogen detection in clinical settings.